LONDON – European scale-up of an artificial intelligence tool for stratifying and personalizing treatment of COVID-19 patients according to the type of complications they are likely to experience will get underway in September, following initial validation. The tool, developed by researchers at the Hospital Clinic Barcelona, Spain, was ‘trained’ on more than a trillion anonymized data points retrieved from the clinic’s electronic health records system.
Deep Lens Inc.’s artificial intelligence trial screening and enrollment platform, Viper, will be integrated with Franciscan Health Cancer Center's electronic health record to enable matching of cancer patients with suitable clinical trials starting at diagnosis over the next month. By working together, the two Midwest-based organizations hope to increase the number of patients benefiting from clinical trials and overcome some of the challenges to participation posed by the pandemic.
The U.S. FDA has greenlighted two new modules for Siemens Healthineers’ AI-Rad Companion platform, giving radiologists new artificial intelligence (AI) tools to assist in interpreting magnetic resonance imaging (MRI) studies of the brain and prostate. The AI-Rad Companion Brain MR for Morphometry Analysis and AI-Rad Companion Prostate MR for Biopsy Support join earlier intelligent software modules for Chest CT.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Siemens Healthineers.
Big Health’s digital therapeutic Sleepio may not only improve insomnia but also reduce symptoms of depression, a study to be published Aug. 19 in the Journal of Sleep Research shows.
TORONTO – Virtual reality (VR) platform developer Realize Medical Inc. is collaborating with Lausanne, Switzerland’s Logitech International SA on what the Ottawa-based med tech calls “the world’s first VR platform for creating patient-specific 3D medical models.”
Tech-enabled diabetes and chronic conditions management company Cecelia Health has secured $13 million in a series B financing led by Rittenhouse Ventures and Endo Investors. Other participants in the round included Boston Millennia Partners, SustainVC and G100 Capital. The funds will be used to speed and further scale adoption of the company’s coaching and telemedicine tools and to build out digital health capabilities.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Boston Scientific, Life Spine, Magventure, United Imaging.
Sight Diagnostics Ltd. raised $71 million in series D financing to expand its commercial operations and increase research and development efforts into disease detection from its fingerprick blood analyzer Sight OLO.
Investigators have developed a new approach to classifying neurodegenerative disorders that used the overall patterns of protein aggregation, rather than specific proteins, to define six clusters of patients that crossed traditional diagnostic categories.
RSS
